Member Info for PL75

‘The two-weekly dosing study will aim to take patients with a more defined set of cancers than was the case in the three-weekly study and these may also have different treatment histories. This is designed to help further inform the choice of indications for the Phase 2 study. If it is possible to enrol patients earlier in their treatment journey then that is a decision for the treating oncologist.’

They answered loads of questions in the investormeet q&a, including a question about ADCs - answer, there’s room for both. No need to ask them every two months.

‘The two-weekly dosing study will aim to take patients with a more defined set of cancers than was the case in the three-weekly study and these may also have different treatment histories. This is designed to help further inform the choice of indications for the Phase 2 study. If it is possible to enrol patients earlier in their treatment journey then that is a decision for the treating oncologist.’

That's why you don't reply on their disruptive threads - they subsequently report them themselves to get them taken down after they've humiliated themselves. Just report and ignore or bin. We know who the trolls are and new incarnations aren't difficult to spot.

Ah Myles, the voice of 'the majority' who peddles some really stupid ideas - yes, let's flog Dx at a loss and retain the debt. I'd rather keep him clear.

Rather than setting up more coffee and cake sessions, just collate them and then publish any responses so that all investors receive the same information. Also, the example given is terrible. They've had an affimer sales pitch on their website for years describing superiority over antibodies - it's done nothing commercially. Creating another pamphlet for pre|Cision over ADCs does nothing other than give cosy feelings. I'd prefer not to waste their time answering pointless questions and get out there selling it to long term investors and BP rather than pandering PIs. They've hired someone to do just that. They answered a LOT of questions following the last InvestorMeet for a change. Just request a quarterly InvestorMeet rather than half yearly and be more organised with the questions at that point.

If only the article had said fortnightly treatments, that’d have been a pump fit for a king

I’m not a subscriber to the Twatter school of commercial stupidity. Latest brilliant idea is flogging Dx at a 10m loss. Brilliant idea. Lose a profitable revenue stream and keep a chunk of debt. All whilst speaking on behalf of ‘the majority’. Idiots.

As I said, hypocritical moron. Bye.

GST Interim results. ‘Net loss for the period of US$737,000 (H1 2022: US$1,153,000 loss)’

Financially illiterate hypocritical moron.

Strangy, eggy does not have panache, a hollow shell of his former self/account

And QBT looks like a tremendous steaming pile of excrement. Another company with whopping losses. Sort your own awful portfolio out before interfering with anyone else’s.

AHS, you’re invested in GST. They’re losing whopping amounts of cash. Suppose you’re invested in that ‘business’ for the potential. Hypocritical cretin.

AHS, gotta wonder why you care about someone else’s opinion of a ‘business’ you’re not invested in. Perhaps next time someone mentions £20 just chuckle and move on. Another day, another account, more sulphuric stench. How many accounts are in THE ROOM?

AHS, no one (apart from the ramping twatterati) is saying this should be valued at £20 today. There is potential that it could be at some point based on either licencing / deals which lead to sufficient funding to get ava6k to market or an overnight leap based on BP making a takeover approach. It might be £20, it might be £8, it might be £50. The potential of the platform and the IP is the investment case. It's an early stage biotech that's now in the clinic, it's currently priced at the value the market believes it's worth, no opinion needed. As things progress that'll change. It's a long term investment and the rainbow chasers looking for overnight big gains would be better off in a casino. Another day, another collection of pointless FUD and on for 100 posts again. There's nothing to talk about right now.

ATS, that’s easy, they’ll take over the fapalicious dox market worth 1.5bn pa and expand it due to more cycles and a broader age range. An extremely low PE ratio would see you well over £6bn. That’s just one example, there’s a pipeline of them, never mind licensing opportunities. You sure you’re researched?

Btw, not ‘sure’ what the ‘quotes’ were ‘for’. It’s ’definitely’ a ‘business’.

AHS, currently it’s mainly the IP. Hope that helps.

"Can you not just wait until the company reveals IT to us"

What? After the Dx / death spiral debacle you're now saying they're branching out in to IT services? Where's the strategy Alan...

Oops. Seems Eggy is back. My fault for mentioning pitiful embarrassing twats. Soz everyone, shouldn't have called him out by name.

Christ, where do they wheel these twats in from? The standard of dewamping is genuinely pitiful nowadays. The best they can muster is the ‘concern’ someone changed jobs and that something that’s already proven ‘it works’ might not work after all. Still, at least the basics are there… six figure holding and ‘concerns’. Must try harder.